Home > News > Welcome to My Tiny World
July 10th, 2007
Welcome to My Tiny World
Abstract:
Venture capital company Harris & Harris Group (Nasdaq: TINY) specializes in tiny technology. The Fool's Jack Uldrich recently interviewed Charles Harris, CEO of this March 2005 Motley Fool Rule Breakers recommendation, and learned about Harris & Harris' investments in nanotech start-ups, its high-risk, high-reward investment philosophy, the effects of Sarbanes-Oxley, and more.
Jack Uldrich: What is Harris & Harris Group, and how are you different from your peers?
Charles Harris: In most respects, we are a rather conventional venture capital firm. We co-invest with a wide variety of other venture capital firms, as well as industrial companies, in start-up and early-stage companies based on novel technologies. We are, however, different in two respects: Because we are a publicly held company and invest only our own capital, we have permanent capital; and we invest only in companies that are working with what MIT terms "tiny technology," which in our case usually means nanoscale technology.
Source:
fool.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||